Haematology Research
Studies that you can join now
STUDY TITLE
PETReA: Phase 3 evaluation of PET-guided, Response-Adapted therapy in patients with previously untreated, high tumour burden follicular lymphoma
What is the study about?
The study is trying to improve treatment for people with follicular lymphoma who need drug treatment for the first time. The study is using a type of body scan called PET-CT to split patients into two groups based on how long their disease is likely to stay away after initial treatment. Those patients whose disease is likely to come back sooner rather than later will be randomly assigned to one of two types of extended treatment, while those whose disease is likely to stay away for a long time will be randomly assigned to receive extended treatment or no further treatment to see how the pros and cons of the two approaches balance out.
Who can take part?
People with follicular lymphoma who need drug treatment for the first time.
Research contact and further information
Jessie Huang, Research Nurse
Dr Barbara Hammer, Consultant Haematologist
Email: wih-tr.ResearchDepartment@nhs.net
Tel: 0151 604 7545
____________________________________________________________________________________________________________________
STUDY TITLE
MITHRIDATE: Ruxolitinib versus hydroxycarbamide or interferon as first line therapy in high risk polcythemia vera (PV) - a phase III randomised trial
What is the study about?
The aim of this research study is to test how safe and effective a drug called ruxolitinib is when treating patients with PV when compared to the current Best Available Therapy (BAT).
Who can take part?
People with high risk PV
Research contact and further information
Jessie Huang, Research Nurse
Dr Elizabeth Jones, Consultant Haematologist
Email: wih-tr.ResearchDepartment@nhs.net
Tel: 0151 604 7545
____________________________________________________________________________________________________________________
STUDY TITLE
PROPEL: Evaluation of PeRsOnalised PrEhabilitation in people with acute myeloid Leukaemia
What is the study about?
Treatment for Acute Myeloid Leukaemia (AML) and Myelodysplastic syndrome with excess blasts (MDS-EB2) is extremely challenging and patients often feel very tired (fatigued) have low mood, poor nutrition and be unable to do any exercise. Programmes that help patients improve their overall health and fitness before major treatment is called prehabilitation. This study aims to see if a personalised prehabilitation package which includes remote support for emotional wellbeing, nutrition and exercise can help patients get through all cycles of intensive chemotherapy and stem cell transplant (if given), as well as reduce tiredness, improve quality of life, and treatment outcomes for patients with AML and MDS-EB2.
Who can take part?
People who have been diagnosed with AML or MDS with excess blasts and are, or their blood results suggest they are likely to be in remission after induction chemotherapy. They will also be planning to undertake consolidation chemotherapy with or without a stem cell transplant.
Research contact and further information
Jessie Huang, Research Nurse
Email: wih-tr.ResearchDepartment@nhs.net
Tel: 0151 604 7545
____________________________________________________________________________________________________________________